[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Beth Israel Deaconess Medical Center\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":663},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,76,0,25,[9,52,78,102,130,165,190,215,239,264,290,320,341,371,398,420,447,478,498,519,540,570,591,616,639],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100584635","groceries-for-residents-of-southeastern-usa-to-stop-hypertension-100584635",false,"NCT06891911","Groceries for Residents of Southeastern USA to Stop Hypertension","GoFreshSE","Inclusion Criteria:\n\n1. Resting systolic blood pressure of 120 to \\\u003C160 mm Hg and diastolic blood pressure \\\u003C110 mm Hg\n2. Resident of Florida, Georgia, and Tennessee\n3. Able to receive home-delivered groceries or pick them up at a convenient location and willing to eat only the groceries provided over a 4-week period\n4. Have access to refrigeration, cooking appliances, and Wi-Fi\u002Fcellular service\n5. Have access to mobile device or computer to be able to conduct grocery orders via video conference and send\u002Freceive text messages\n6. Willing and able to complete required measurement procedures\n7. Able to provide consent for the study\n8. Has access to a primary care team, urgent care center, or emergency room the study team can refer to for follow up care if warranted during the study\n\nExclusion Criteria:\n\nA. Laboratory Exclusions:\n\n1. Serum potassium ≥5.4 mmol\u002FL or \\\u003C3.5 mmol\u002FL\n2. Estimated glomerular filtration rate (eGFR) \\\u003C30 mL\u002Fmin per 1.73 m\\^2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation\n3. Hemoglobin A1c ≥6.5%\n\nB. Medication Exclusions:\n\nUnstable doses (i.e. a change in the 6 months prior to screening or randomization or planning to start within study period) of the following:\n\n1. GLP-1 and dual GLP-1\u002FGIP receptor agonists\n2. Anti-hypertension medications\n3. Sodium-glucose co-transporter 2 (SGLT2) inhibitors\n4. Glucose lowering medications\n\nUse of any of the following medications:\n\n1. Potassium supplement, except if part of a multivitamin\n2. Warfarin (Coumadin)\n3. Chronic oral corticosteroid (intermittent use is okay)\n4. Weight loss medications (non-GLP-1 receptor agonists)\n5. Sulfonylurea or any insulin use\n\nAny medication not compatible with participation as determined by the investigators\n\nC. Physical Exclusions:\n\n1. Systolic blood pressure: \\\u003C120 or ≥160 mm Hg or diastolic blood pressure ≥110 mm Hg\n2. Arm circumference \\>52 cm (or the upper limit of the validated BP device)\n\nD. Medical History Exclusions:\n\n1. Self-reported weight loss or gain of 15 pounds during prior 2 months\n2. Active cardiovascular disease or any event in the prior 6 months, including coronary artery bypass grafting (CABG), percutaneous transluminal coronary angioplasty (PTCA), myocardial infarction (MI), cerebrovascular accident (CVA), or congestive heart failure (CHF) exacerbation requiring hospital admission\n3. Cancer diagnosis or treatment in the last 2 years (non-melanoma skin cancer or localized breast or prostate or bladder cancer not requiring systemic therapy is acceptable)\n4. Gastrointestinal surgery or history that affects nutrition absorption or requires a specific diet that will deter DASH diet adherence\n5. Pregnancy or lactation or planned pregnancy during the study period\n6. Any emergency department (ED) visit for asthma or chronic obstructive pulmonary disease (COPD) in the last 6 months\n7. Hypoglycemia hospitalization in the last 12 months\n8. Any other serious illness or condition not compatible with participation as determined by the investigators\n\nE. Lifestyle and Other Exclusions:\n\n1. Significant food allergies, preferences, intolerances, or dietary requirements that would interfere with diet adherence\n2. Consumption of more than 14 alcoholic drinks per week or consumption of more than 6 drinks on one or more occasion per week\n3. Active substance use disorder that would interfere with participation\n4. Extreme food insecurity\n5. Participation in or planning to start weight loss program\n6. Current participation in another clinical trial that could interfere with the study protocol\n7. Anticipated change in residence outside of eligible states prior to the end of the study\n8. Families with more than 6 adults at dinner time (children count as half an adult)\n\nF. Investigator discretion",true,"ALL","18 Years",{"count":21,"type":22},150,"ESTIMATED","INTERVENTIONAL",[25],"NA","GoFreshSE is a randomized control trial, testing the effects of a home-delivered, dietitian-assisted, DASH-patterned grocery intervention on blood pressure in adults with high blood pressure in Florida, Georgia, and Tennessee.",[28,29,30,31],"Hypertension","Elevated Blood Pressure","Cardiovascular Diseases","Dietary Intervention",[28,33,34,35,36,37,38],"Dash Diet","Low Sodium","Diet","Nutrition","Clinical trial","Dietitian","RECRUITING","2026-08-18",{"date":42,"type":43},"2026-08-19","ACTUAL",{"date":45,"type":43},"2025-10-14",{"date":47,"type":22},"2026-12",{"name":49,"class":50},"Beth Israel Deaconess Medical Center","OTHER",1,{"id":53,"slug":54,"hasResults":12,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":60,"targetDuration":4,"studyType":23,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":51},"100624080","phase-2-reversal-of-spinal-anesthesia-residual-motor-block-via-intrathecal-catheter-100624080","NCT07404982","Reversal of Spinal Anesthesia Residual Motor Block Via Intrathecal Catheter","Reversal of Spinal Anesthesia Residual Motor Block Via Intrathecal Catheter: A Pilot Study","IT-Cath","Inclusion Criteria:\n\n1. Patients having elective lower extremity joint replacement surgery\n2. Patients \\>18 years\n\nExclusion Criteria:\n\n1. Contraindications to spinal anesthesia (refusal, lumbar spinal hardware, spinal abnormalities)\n2. Patient on anticoagulation not withheld\n3. Patient receiving re-operation on the same joint\n4. Prior intra-cranial bleeding\n5. Patient's ASA status \\>3\n6. Non-English speaking\n7. Bromage score of 6 at the time of first PACU assessment post-enrollment",{"count":61,"type":22},24,[63],"PHASE2","The purpose of this study is to determine the feasibility of administering a predetermined amount of normal saline into the intrathecal or subarachnoid space via a small spinal catheter to reduce or eliminate the effects of previously injected spinal anesthetic following lower extremity orthopedic surgery.",[66],"Joint Replacement Surgery",[68,69],"Joint Replacement","Knee Replacement","2026-07-30",{"date":72,"type":43},"2026-07-31",{"date":74,"type":43},"2026-03-19",{"date":76,"type":22},"2027-12",{"name":49,"class":50},{"id":79,"slug":80,"hasResults":12,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100649812","nad-supplementation-to-reduce-the-incidence-of-cardiac-surgery-associated-acute-kidney-injury-100649812","NCT07739290","NAD Supplementation to Reduce the Incidence of Cardiac Surgery Associated Acute Kidney Injury","Inclusion Criteria:\n\n1. Age ≥18 years\n2. Undergoing coronary artery bypass graft (CABG) and\u002For valve surgery with cardiopulmonary bypass (CPB) at BIDMC. Includes combination surgeries that involve CABG and\u002For valve plus other procedures (e.g., Maze procedure, aortic aneurysm repair).\n3. AKI risk score ≥6 at the time of screening\n\nExclusion Criteria:\n\n1. History of AKI in the seven days prior to surgery, defined as any of the following:\n\n   * Increase in serum creatinine ≥0.3 mg\u002Fdl in 48h\n   * Increase in serum creatinine ≥50% in 7d (if no value available in last 7d, use most recent value in last 3 months)\n   * Urine output ≤0.5 ml\u002Fkg\u002Fh x 6 consecutive hours (only assessed in patients with hourly monitoring via Foley catheter)\n   * Receipt of renal replacement therapy (RRT) within 7d\n2. Advanced chronic kidney disease (eGFR \\\u003C15 ml\u002Fmin\u002F1.73m2 or end-stage kidney disease receiving RRT)\n3. Pregnant or breastfeeding\\*\n4. Positive COVID test in the last 10 days.\n5. Prisoner or institutionalized\n6. Existing or anticipated durable VAD\n\n8\\. Conflict with other studies\n\n9\\. Previous usage of nicotinamide supplements in the past 30 days",{"count":85,"type":22},20,[25],"The purpose of this single-center, randomized, double-blinded placebo-controlled pilot trial is to demonstrate feasibility and help design a larger trial to assess the effectiveness of nicotinamide (NAM) supplementation in reducing risk of post-operative AKI in patients undergoing cardiac surgery.",[89],"Acute Kidney Injury",[91,92,93],"Acute kidney injury","nicotinamide adenine dinucleotide","cardiac surgery","NOT_YET_RECRUITING","2026-07-29",{"date":72,"type":43},{"date":98,"type":22},"2026-09-01",{"date":100,"type":22},"2029-01-01",{"name":49,"class":50},{"id":103,"slug":104,"hasResults":12,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":111,"briefSummary":112,"conditions":113,"keywords":117,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":51},"100641249","phase-2-the-cardioprotect-trial-100641249","NCT07654426","The CARDIOPROTECT Trial","A Randomized Study of Dexrazoxane or Liposomal Doxorubicin in Newly Diagnosed Diffuse Large B-cell Lymphoma at High Risk for Heart Failure Events: the CARDIOPROTECT Trial","Inclusion Criteria:\n\n* Participants must have histologically confirmed diffuse large B-cell lymphoma, histologically transformed large B cell lymphoma from a prior indolent lymphoma, or other high-grade B-cell lymphoma for which R-CHOP or pola-R-CHP are planned. Any cancer stage is permitted.\n* Participants must not have received any prior chemotherapy for this malignancy. Pre-phase steroids are allowed. Prior treatment for a different malignancy is allowed, including prior treatment for indolent lymphoma.\n* Age ≥18 years. Diffuse large B cell lymphoma is rare in participants \\\u003C18 years of age. The prevalence of HF prior to chemotherapy is also exceedingly rare in participants \\\u003C18 years of age; therefore, participants \\\u003C18 years of age are excluded from this study.\n* Participants must have ONE or more of the following risk factors for HF events with anthracycline-containing chemotherapy\n\n  1. LVEF 30-50% on most recent echocardiogram with or without HF history\n  2. LVEF 50% with a history of HF (i.e. HF with improved EF or HF with preserved EF).\n  3. History of anthracycline exposure for different malignancy.\n* Participants with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n* Because dexrazoxane as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 4 months after completion of chemotherapy administration.\n* Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n* New York Heart Association (NYHA) Class III or IV exertional dyspnea. The symptoms should be attributed to HF and not due to lymphoma, anemia, arthritis or other causes per the assessment of the treating clinician or study investigator. NYHA Class III defined as: \"Marked limitations with less than ordinary activity such as walking short distances or climbing a few stairs\" and NYHA Class IV defined as: \"Inability to carry out any activity without discomfort. Symptoms are present at rest and if any physical activity is undertaken the symptoms are increased.\" (see Appendix A for NYHA Classification).\n* LVEF \\\u003C30% on most recent echocardiogram. Patients with prior LVEF \\\u003C30% with improvement to \\>30% on most recent echocardiogram are eligible.\n* Meeting criteria for frailty according to the simplified geriatric assessment (see Appendix A for the simplified geriatric assessment criteria).\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to any agents used in study.\n* Presence of central nervous system involvement\n* Presence of concurrent genetic rearrangements of the MYC and BCL2 genes, so called \"double-hit\" large-cell lymphoma who are not deemed eligible for intensified induction chemotherapy such as dose adjusted EPOCH-R by their treating physician can be enrolled\n* Ineligible for R-CHOP or pola-R-CHP because of liver disease per institutional policies\n* Patients with planned dose reductions from the first cycle ie R-mini-CHOP will be excluded\n* There are no contraindicated medications. Caution and monitoring are advised with medications that can cause myelosuppression.\n* Patients with positive Hepatitis B core antibody can be enrolled if they have negative viral load and can be maintained on antiviral prophylaxis\n* Patients with HIV can be enrolled if they have anti-retroviral therapy options without drug-drug interactions with the cancer treatment, agree to take anti-retroviral therapy and do not have uncontrolled opportunistic infections.\n* Pregnant women are excluded from this study because dexrazoxane and liposomal doxorubicin are agents with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with dexrazoxane and liposomal doxorubicin, breastfeeding should be discontinued if the mother is treated with dexrazoxane and liposomal doxorubicin. These potential risks may also apply to other agents used in this study.\n* Eligibility for observational arm of the study. The above inclusion and exclusion criteria are for the randomized trial. Patients who meet the inclusion criteria but have one or more exclusion criterion are eligible to participate in the observational arm of the study. In addition, patients who meet all eligibility criteria for the randomized trial but decline participation in the randomized trial are also eligible to participate in the observational arm of the study.",{"count":110,"type":22},60,[63],"This trial is to evaluate if dexrazoxane is safer and more effective than liposomal doxorubicin in preventing heart failure events in participants with diffuse large B-cell lymphoma (DLBCL) undergoing either standard of care R-CHOP or pola-R-CHP treatment regiments.\n\nThe names of the study drugs involved in this study are:\n\n* Dexrazoxane (a type of Topoisomerase II Inhibitor)\n* Liposomal Doxorubicin (a type of Topoisomerase II Inhibitor)\n* Standard of care R-CHOP treatment regimen (Cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab)\n* Standard of care pola-R-CHP treatment regimen: Cyclophosphamide, doxorubicin, polatuzumab vedotin-piiq, prednisone, rituximab",[114,115,116],"Diffuse Large B-cell Lymphoma (DLBCL)","Cardiotoxicity","Lymphoma",[114,118,115,116,119,120,121],"High Risk for Heart Failure Events","Stage B Heart Failure","Stage C Heart Failure","Left ventricular ejection fraction (LVEF) decline","2026-07-24",{"date":124,"type":43},"2026-07-27",{"date":126,"type":22},"2026-08-31",{"date":128,"type":22},"2035-12-31",{"name":49,"class":50},{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":17,"sex":18,"minAge":137,"maxAge":19,"enrollmentInfo":138,"targetDuration":4,"studyType":23,"phases":140,"briefSummary":141,"conditions":142,"keywords":146,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":51},"100606288","transforming-adolescent-perception-and-mental-health-through-meditation-and-cognitive-reappraisal-a-mixed-method-study-100606288","NCT07173608","Transforming Adolescent Perception and Mental Health Through Meditation and Cognitive Reappraisal A Mixed Method Study","THRIVE","Inclusion Criteria:\n\n* Individuals between15-18 years of age\n* Ability to understand study instructions and provide informed consent\u002Fassent. (parental consent for minors)\n* Access to internet and a device to complete online study activities\n* Currently residing in the United States\n* Willing and able to travel to the hospital location in Boston for study procedures.\n\nExclusion Criteria:\n\n* Non-English speaking (Justification: the intervention and assessment instruments are not validated in a sufficient range of languages, and the research team lacks polylingual capabilities or the financial resources to hire interpreters for the duration of all proposed assessments.)\n* Practicing meditation regularly in the past 6 months (4 or more times per week for 4 weeks or more in the past 6 months)\n* History of psychiatric illness such as severe anxiety, severe depression, posttraumatic stress disorder (PTSD), Schizophrenia or bipolar disorder\n* Current use of cognition enhancing drugs\n* Current management for chronic pain\n* History (within past 5 years) of seizure, brain surgery or any condition causing cognitive decline.\n* Active history (within the last 5 years) of alcohol or drug abuse.\n* Current pregnancy or planning to become pregnant in the next 6 months\n* Currently enrolled in another interventional study that could impact the primary outcome, as determined by the PI\n* Significant visual impairment\n* Subject has previously learned the intervention.\n* Subject has contraindications for MRI (Detailed in the eligibility screening questions)","15 Years",{"count":139,"type":22},96,[25],"This study will evaluate how a comprehensive meditation-based program, Inner Engineering, supports teens ages 15-18 in becoming more joyful, focused, resilient, and better equipped to manage stress and thrive. Through this study, researchers will examine whether practices like meditation, yoga, and cognitive reframing can help adolescents view and respond to challenges with greater clarity and balance. The study will assess mental and physical impacts through self-report, physiological, and neuroimaging methods.",[143,144,145],"Meditation","Cognitive Reappraisal","Emotional Regulation",[147,148,149,150,151,152,153,154,155,156],"meditation","Inner Engineering","Shambhavi Mahamudra Kriya","EEG","Functional MRI","MRI","Cognition","Mindfulness","Mental Health","Adolescent","2026-07-19",{"date":159,"type":43},"2026-07-21",{"date":161,"type":43},"2026-05-01",{"date":163,"type":22},"2028-03",{"name":49,"class":50},{"id":166,"slug":167,"hasResults":12,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":12,"sex":172,"minAge":19,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":23,"phases":175,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":182,"lastUpdatePostDateStruct":183,"startDateStruct":185,"completionDateStruct":187,"leadSponsor":189,"locationsCount":51},"100613555","phase-2-pain-control-for-cervical-ripening-balloon-100613555","NCT07268118","Pain Control for Cervical Ripening Balloon","Randomized Control Trial for Pain Control With Topical Lidocaine for Cervical Ripening Balloon Placement","Inclusion Criteria:\n\n* Age ≥18 years\n* Gestational age ≥37 weeks\n* Viable pregnancy\n* Intact membranes\n* English speaking\n* Interested in cervical ripening balloon placement\n* Able to provide consent\n\nExclusion Criteria:\n\n* Allergy or sensitivity to lidocaine\n* Patients that already have neuraxial anesthesia (i.e. spinal, epidural, combined spinal\u002Fepidural)\n* Known uterine or cervical anomalies","FEMALE",{"count":174,"type":22},110,[63],"No standard of care exists for pain management during cervical ripening balloon placement. The purpose of this study is to evaluate if vaginal topical lidocaine reduces pain related to cervical ripening balloon placement during induction of labor.",[178],"Labor Induction",[180,181],"cervical ripening","cervical balloon","2026-07-13",{"date":184,"type":43},"2026-07-15",{"date":186,"type":43},"2026-05-13",{"date":188,"type":22},"2027-06",{"name":49,"class":50},{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":23,"phases":198,"briefSummary":199,"conditions":200,"keywords":204,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":211,"completionDateStruct":212,"leadSponsor":214,"locationsCount":51},"100645481","mechanical-ventilator-adjustments-and-patient-dyspnea-100645481","NCT07701850","Mechanical Ventilator Adjustments and Patient Dyspnea","The Influence of Standard Ventilator Setting Adjustments on Dyspnea Experienced in Awake Mechanically-ventilated Patients: A Pilot Study","Inclusion Criteria:\n\n* Admitted to a participating ICU at BIDMC\n* Requiring mechanical ventilation\n* Awake by both of the following criteria\n* RASS -2 to +2\\*\n* CAM-ICU negative‡\n* Able to communicate\u002Fanswer dyspnea questionnaire\n\n  * RASS (Richmond Agitation-Sedation Scale) is a validated scale commonly used in the ICU to assess patient's level of sedation and agitation. It ranges from -5 to +4. While -5 means an unarousable coma, +4 means violent patient with immediate self danger. The scale from -2 to +2 ranges from light sedation to agitated.\n\n    * CAM-ICU (Confusion Assessment Method) is an ICU validated scale used to assess the presence of delirium. A negative CAM-ICU scale has good positive and negative predictive value to diagnose or exclude delirium.\n\nPhysicians and nurses are trained to evaluate patients using both scales\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old\n* Comfort measures only\n* Hemodynamic instability (MAP \\\u003C 65 mmHg) or increasing requirement of vasopressor\n* PEEP \\> 10 cmH2O\n* FiO2 \\> 0.6\n* Current Prone position\n* Current Pneumothorax\n* Bronchopleural fistula\n* Neuromuscular conditions that impair responding to the dyspnea scale or expression\n* Dementia\n* Prisoners\n* Pregnant women\n* Patients intubated and ventilated for less than 12 hours during the current ventilation episode\n* pH \\\u003C 7.20 or \\> 7.55\n* Presence of chest tube\n* Status post thoracotomy\n* Treating clinician refusal",{"count":85,"type":22},[25],"In the past 5 years, there are increasing data suggesting that patients treated with mechanical ventilation experience shortness of breath, despite appropriate sedation. This adverse experience is believed to contribute to the finding that up to 25% of patients who survive severe respiratory diseases experience mental health problems including post traumatic distress syndrome (PTSD). The purpose of this study is to evaluate if\u002Fhow sequential changes in the delivery of mechanical ventilation affect shortness of breath sensation in awake patients requiring mechanical ventilation. Improving the knowledge of the impact of the patient-ventilator interaction on shortness of breath sensation may lead to strategies to improve the comfort of non-sedated and sedated ventilated patients, and thereby reduce mental health sequelae in survivors of acute severe respiratory diseases The investigators hypothesize that current ventilator strategies, particularly reduced tidal volume (size of breath given by the ventilator) utilized in managing patients with severe respiratory diseases, contribute to shortness of breath in patients with increased drive to breathe. In this setting, some safe ventilator changes may improve or worsen the shortness of breath sensation in awake patients on mechanical ventilation.",[201,202,203],"Respiratory Failure","Dyspnea During Mechanical Ventilation","Mechanical Ventilation",[205,206,207],"respiratory failure","mechanical ventilation","dyspnea","2026-07-08",{"date":210,"type":43},"2026-07-14",{"date":98,"type":22},{"date":213,"type":22},"2027-07-01",{"name":49,"class":50},{"id":216,"slug":217,"hasResults":12,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":222,"targetDuration":4,"studyType":23,"phases":223,"briefSummary":224,"conditions":225,"keywords":227,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":232,"lastUpdatePostDateStruct":233,"startDateStruct":235,"completionDateStruct":236,"leadSponsor":238,"locationsCount":51},"100613180","phase-2-the-safety-and-efficacy-of-roflumilast-foam-in-hs-100613180","NCT07263230","The Safety and Efficacy of Roflumilast Foam in HS","An Open-label Single Center Study Evaluating the Safety and Efficacy of Roflumilast Foam 0.3% in Subjects With Hidradenitis Suppurativa","Inclusion Criteria:\n\n1. Male or female subjects aged 18 years or older\n2. Participants are legally competent to sign and give informed consent.\n3. Diagnosis of HS based on clinical history and physical examination for at least 3 months.\n4. Diagnosis of HS (Hurley I or II) with a total AN count of at least 4 to ≤ 10, with no draining tunnels at screening and baseline visits with an AN of \\>4 affecting at least one distinct anatomical region.\n5. Agreement to NOT use topical and systemic antibiotics and intralesional steroids for treatment of HS during the study.\n6. Agreement to NOT use a diluted beach bath or topical antiseptic washes containing chlorhexidine gluconate or benzoyl peroxide on the areas affected by HS lesions during the study.\n7. Subjects who have had surgery in the treatment area should be at least 3 months post procedure (this applies to deroofing\u002F marsupialization or excision, not incision \\& drainage)\n8. Females of childbearing potential (FOCBP) must have a negative urine pregnancy test at Screening and Baseline\u002FDay 1. In addition, sexually active FOCBP must agree to use at least one form of a highly effective or barrier method of contraception throughout the trial. The use of abstinence as a contraceptive measure is acceptable if this is a consistent part of a lifestyle choice and an acceptable backup method has been identified if the subject becomes sexually active.\n9. Females of non-childbearing potential should be post-menopausal with spontaneous amenorrhea for at least 12 months or have undergone surgical sterilization (permanent sterilization methods include hysterectomy, bilateral oophorectomy, hysteroscopic sterilization, bilateral tubal ligation or bilateral salpingectomy).\n10. In good health as judged by the Investigator, based on medical history, targeted physical examination, and vital signs. Subjects and parent(s)\u002Flegal guardian(s) are considered reliable and capable of adhering to the Protocol and visit schedule, according to the judgment of the Investigator.\n\nExclusion Criteria:\n\n1. Subjects with any medical condition or physical examination abnormality that would prevent study participation or place the subject at significant risk, as judged by the Investigator\n2. Subjects who cannot discontinue medications and treatments prior to the Baseline visit and during the study according to Excluded Medications and Treatments (see table of Excluded Medications and Treatments with washout timelines).\n3. Presence of draining tunnels at screening or at baseline visits\n4. Subjects who are unwilling to refrain from prolonged sun exposure and from using a tanning bed or other artificial light emitting devices (LEDs) for 4 weeks prior to Baseline\u002FDay 1 and during the study.\n5. Subjects with skin conditions other than HS that would interfere with evaluations of the effect of the study medication on HS, as determined by the Investigator.\n6. Subjects with any condition on the treatment area which, in the opinion of the Investigator, could confound efficacy measurements.\n7. Known allergies to excipients in Roflumilast foam (petrolatum, isopropyl palmitate, methylparaben, propylparaben, diethylene glycol monoethyl ether, hexylene glycol, cetylstearyl alcohol, dicetyl phosphase and ceteth-10 phosphate).\n8. Subjects who cannot discontinue the use of systemic CYP3A4 inhibitors or dual inhibitors that inhibit both CYP3A4 and CYP1A2 simultaneously for 2 weeks prior to Baseline\u002FDay 1 and during the study period.\n9. Subjects who have received oral roflumilast (Daxas®, Daliresp®) within 4 weeks prior to Baseline\u002F Day 1.\n10. History of severe depression, suicidal ideation or behavior at Baseline\u002FScreening\n11. Females who are pregnant, wishing to become pregnant during the study, or are breast-feeding.\n12. Previous treatment with Roflumilast cream or foam (any potency) or current Roflumilast use for any other indication at the baseline visit that would be expected to continue during the trial.\n13. Subjects with a history of major surgery within 4 weeks prior to Baseline\u002FDay 1 or subjects who have major surgery planned during the study.\n14. Subjects with a history of chronic alcohol or drug abuse within 6 months prior to Screening.\n15. Current or a history of cancer within 5 years except for fully treated skin basal cell carcinoma, cutaneous squamous cell carcinoma or carcinoma in situ of the cervix.\n16. Parent(s)\u002Flegal guardian(s) who are unable to communicate, read, or understand the local language(s). Subjects who are unable to communicate, read or understand the local language, or who display another condition, which in the Investigator's opinion, makes them unsuitable for clinical study participation.\n17. Subjects who are family members of the clinical study site, clinical study staff, or sponsor, or family members of enrolled subjects living in the same house.",{"count":85,"type":22},[63],"This study investigates the efficacy of topical roflumilast foam in patients with HS.",[226],"Hidradenitis Suppurativa (HS)",[228,229,230,231],"HS","Hidradenitis Suppurativa","Roflumilast","Topical medication","2026-07-07",{"date":234,"type":43},"2026-07-09",{"date":98,"type":22},{"date":237,"type":22},"2029-05",{"name":49,"class":50},{"id":240,"slug":241,"hasResults":12,"nctId":242,"briefTitle":243,"officialTitle":244,"acronym":245,"eligibilityCriteria":246,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":247,"enrollmentInfo":248,"targetDuration":4,"studyType":23,"phases":250,"briefSummary":251,"conditions":252,"keywords":255,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":261,"completionDateStruct":262,"leadSponsor":263,"locationsCount":51},"100582750","reducing-psychological-distress-to-optimize-recovery-of-elderly-icu-survivors-and-caregivers-restore-icu-100582750","NCT06867367","REducing pSychological diSTress To Optimize Recovery of Elderly ICU Survivors and Caregivers (RESTORE-ICU)","REducing pSychological diSTress To Optimize Recovery of Elderly ICU Survivors and Caregivers (RESTORE-ICU): A Pilot Feasibility Study","RESTORE-ICU","Patient Inclusion\u002FExclusion Criteria\n\nInclusion Criteria:\n\n1. Provide signed and dated informed consent and understand the nature of the study sufficiently to allow completion of all study assessments.\n2. Elderly ICU survivors aged over 60 years who have experienced long ICU stays of more than five days.\n3. Caregivers who either live in the same household as the survivor or visit more than three times a week.\n\nExclusion Criteria:\n\nCo-enrollment in other interventional studies will not be allowed.\n\n1. Age \\>=85 years (Justification: Assessment instruments not validated in this age group and patients in extremes of age may have limited proficiency to engage in proposed meditative practices)\n2. Non-English speaking\u002FLow-English proficiency (Justification: assessment instruments are not validated in a sufficient range of languages, and the research team lacks polylingual capabilities or the financial resources to hire interpreters for the duration of all proposed assessments.)\n3. Non-US resident\n4. Recent or current meditation, yoga, breathwork or associated MBI intervention practice (\\> 2 times per week). (Justification: as the primary outcome is to evaluate the feasibility and adherence of patients to a multicomponent MBI, recent or current practice of the individual or combined components would directly influence the endpoint).\n5. Individuals discharged to a non-home location, such as a rehabilitation center, nursing home, or long-term acute care facility.\n6. Individuals with limited internet access, which would prevent access to online guided meditation\n7. Prisoners.\n8. Individuals who refuse to participate in the study.\n9. Not on vasopressor or inotropic support at the time of enrollment.\n10. Not on non-invasive ventilation, high-flow nasal cannula (HFNC), or mechanically ventilated.\n11. Not on continuous renal replacement therapy (CRRT).\n12. Failure to pass Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) screening (\\>3.6; Justification: Cognitive decline would limit the ability to engage with and complete the study interventions and assessments).\n13. Scores ≥ 5 on either the anxiety or depression subscales suggesting severe symptom levels.\n14. Known diagnosis of moderate or severe dementia.\n15. Neurological injury.\n16. Residing in a medical institution before admission.\n17. Patient on hospice at or before the time of enrollment.\n18. Mechanical ventilation at baseline or solely for airway protection.\n19. Patient not expected to go home (e.g., transfer to a facility).\n20. Patient not expected to survive two months or expected to transition to hospice.\n21. Patient died in hospital before enrollment.\n22. Attending physician declined enrollment.\n23. Patient discharged before being approached for consent.\n24. Either the patient or caregiver in the dyad declined participation (based on IQCODE or consent).\n\nCaregiver Inclusion\u002FExclusion Criteria\n\nInclusion Criteria:\n\n1. Provide signed and dated informed consent and understand the nature of the study sufficiently to allow completion of all study assessments.\n2. Caregivers who either live in the same household as the survivor or visit more than three times a week.\n3. Age ≥18 years old.\n\nExclusion Criteria:\n\n1. Non-English speaking\u002FLow-English proficiency (Justification: assessment instruments are not validated in a sufficient range of languages, and the research team lacks polylingual capabilities or the financial resources to hire interpreters for the duration of all proposed assessments.)\n2. Non-US resident\n3. Recent or current meditation, yoga, breathwork or associated MBI intervention practice (\\> 2 times per week). (Justification: as the primary outcome is to evaluate the feasibility and adherence of patients to a multicomponent MBI, recent or current practice of the individual or combined components would directly influence the endpoint).\n4. Individuals with limited internet access, which would prevent access to online guided meditation\n5. Prisoners.\n6. Individuals who refuse to participate in the study.\n7. Diagnosed with severe psychiatric disorders, such as schizophrenia, bipolar disorder, or ongoing substance abuse, that could interfere with participation.\n8. Individuals actively receiving treatment for recent trauma\n9. Scores ≥ 5 on either the anxiety or depression subscales suggesting severe symptom levels.\n10. severe or acute medical illness","85 Years",{"count":249,"type":22},14,[25],"This research study aims to explore whether a set of simple breathing techniques and guided meditations can improve the psychological well-being and recovery of ICU survivors and their caregivers.\n\nICU survivors and their caregivers often experience high levels of stress, anxiety, and depression after discharge. This study investigates whether practicing Isha Kriya, a guided meditation, and Nadi Shuddhi, a breathing technique, can support their mental health and relationship quality. These practices are delivered through a mobile app or in a group setting.\n\nParticipants enroll as a caregiver-patient dyad and will engage in these techniques throughout the study. In addition to the practices, brain activity will be recorded using a safe, non-invasive EEG device. The EEG, a lightweight cap with small sensors, measures brainwaves to assess potential changes in brain function and connection. EEG recordings will take place in the hospital during two sessions, each lasting approximately 40 minutes.\n\nParticipants will also complete short surveys at five time points throughout the study, assessing mood, stress, and relationship quality. Baseline demographic information will be collected, and at the conclusion of the study, a brief interview will be conducted to gather feedback on the experience.\n\nThe study spans approximately seven weeks, with the overall goal of determining whether these breathing and meditation practices can provide accessible and scalable mental health support for ICU survivors and their caregivers.",[253,254],"Relationship, Family","Well-Being, Psychological",[256,257,258],"mental health","relationship quality","ICU recovery","2026-07-06",{"date":208,"type":43},{"date":47,"type":22},{"date":76,"type":22},{"name":49,"class":50},{"id":265,"slug":266,"hasResults":12,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":272,"enrollmentInfo":273,"targetDuration":4,"studyType":275,"phases":4,"briefSummary":276,"conditions":277,"keywords":280,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":51},"100533105","testing-health-workers-at-risk-to-advance-our-understanding-of-tb-infection-100533105","NCT06221488","Testing Health Workers At Risk to Advance Our Understanding of TB Infection","THWART-TB: Testing Health Workers At Risk to Advance Our Understanding of TB Infection","THWART-TB","Inclusion Criteria:\n\n* ≥18 years old\n* Health worker\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Prior history of TB or known prior positive IGRA\n* Current or prior history of taking anti-TB treatment","100 Years",{"count":274,"type":22},300,"OBSERVATIONAL","It has been estimated that 1.7 billion people have tuberculosis (TB) infection; yet current tests are unable to predict which people are at highest risk of developing TB disease, which can be life-threatening. THWART-TB is a prospective longitudinal cohort study of health workers (HWs) in Cape Town, South Africa, where our preliminary data reveals HWs have a high annual TB infection risk (34%). This cohort, who will undergo frequent serial evaluation (every 3 months) with a combination of novel assays never previously evaluated together, presents a unique opportunity to evaluate immune responses at the time of initial infection and to characterize the dynamic profile of these immune responses over time in a high-risk population. The knowledge generated will improve our understanding of TB infection and help to identify which people exposed to TB may remain at risk, enabling us to better target preventive strategies.",[278,279],"Tuberculosis","Tuberculosis Infection",[278,281,282,283],"TB","TB infection","Health worker",{"date":208,"type":43},{"date":286,"type":43},"2024-01-15",{"date":288,"type":22},"2029-12-31",{"name":49,"class":50},{"id":291,"slug":292,"hasResults":12,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":296,"eligibilityCriteria":297,"healthyVolunteers":12,"sex":172,"minAge":19,"maxAge":298,"enrollmentInfo":299,"targetDuration":4,"studyType":23,"phases":301,"briefSummary":303,"conditions":304,"keywords":306,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":4},"100646931","phase-4-does-the-volume-of-medication-affect-the-success-of-labor-epidural-analgesia-100646931","NCT07684365","Does the Volume of Medication Affect the Success of Labor Epidural Analgesia","Impact of Injected Volume on Programmed Intermittent Epidural Bolus Analgesia","EpiVol","Inclusion Criteria:\n\n* 18 years of age or older\n* Gestational age of 36 weeks or greater\n* American Society of Anesthesiology physical status 2\n* Induction of labor or early labor (cervical dilation \\\u003C 6cm)\n* Singleton gestation\n* Vertex presentation\n\nExclusion Criteria:\n\n* Preeclampsia\n* Receiving magnesium sulfate\n* Having received narcotics within 4 hours\n* Multiple gestation\n* Major fetal anomalies or demise\n* Previous spine surgery\n* Known major spine pathology\n* Substance use disorder","50 Years",{"count":300,"type":22},70,[302],"PHASE4","The purpose of this study is to evaluate whether changing the volume and concentration of a medication affects the quality of pain relief and the side effects associated with labor epidural analgesia.",[305],"Labor Pain and to Reduce Pain",[307,308,309,310,311,312],"epidural analgesia","Obstetric anesthesia","bupivacaine","fentanyl","programmed intermittent epidural bolus","labor pain","2026-07-02",{"date":259,"type":43},{"date":316,"type":22},"2026-08-15",{"date":318,"type":22},"2027-12-31",{"name":49,"class":50},{"id":321,"slug":322,"hasResults":12,"nctId":323,"briefTitle":324,"officialTitle":324,"acronym":325,"eligibilityCriteria":326,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":327,"targetDuration":4,"studyType":23,"phases":329,"briefSummary":330,"conditions":331,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":340},"100497191","building-respiratory-support-in-east-africa-through-high-flow-versus-standard-flow-oxygen-evaluation-100497191","NCT05754034","Building Respiratory Support in East Africa Through High Flow Versus Standard Flow Oxygen Evaluation","BREATHE","Inclusion Criteria:\n\n* age\\>=18 years AND\n* admitted to a study site hospital within the 24 hours prior to screening AND\n* SpO2\\\u003C90% at time of first assessment OR\n* receiving oxygen at time of first assessment\n\nExclusion Criteria:\n\n* imminent death (high clinical suspicion of death within 24 hours of admission)\n* patient or caregiver refusal of study participation\n* history of chronic respiratory failure (SpO2\\\u003C90% or oxygen dependence for at least three months)\n* anatomical factors precluding the use of nasal cannula\n* intubation or non-invasive ventilation by the clinical team prior to screening for the trial\n* known hypoxemia at transferring facility for \\>48 hours\n* lack of availability of either SFO or HFO devices or supplies at the time of randomization.",{"count":328,"type":22},1600,[25],"Acute hypoxemia is common and deadly in resource variable settings. While studies in high income countries (HICs) have indicated a possible benefit to high flow oxygen as compared with standard flow oxygen, rigorous studies in low or lower middle income countries (LMICs) have not been performed. Studies in sepsis have demonstrated that interventions that improve outcomes in one context may actually be neutral or harmful in a different context.\n\nThe goal of this study is to test whether high flow oxygen results in better outcomes for hypoxemic adult patients, as compared with standard flow oxygen, in five LMIC hospitals. The main questions it aims to answer are:\n\n1. For hypoxemic adults in these LMIC study settings, does high flow oxygen or standard flow oxygen result in lower mortality?\n2. What are the facilitators and barriers to using high flow oxygen in these settings?\n3. Does high flow or standard flow oxygen use more oxygen?\n\nParticipants will be randomized to receive either high flow oxygen through a large nasal cannula, or to receive standard flow oxygen, through nasal cannulas, face masks, or non-rebreather masks. Researchers will compare the outcomes for the two groups, to see if one group of patients has better outcomes than the other.\n\nThe study will also examine how much oxygen is used by the two patient groups, as well as other factors relevant to the feasibility of implementation of high flow oxygen in these sites.",[332],"Acute Hypoxemia","2026-07-01",{"date":259,"type":43},{"date":336,"type":43},"2023-10-11",{"date":338,"type":22},"2026-12-31",{"name":49,"class":50},5,{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":23,"phases":351,"briefSummary":353,"conditions":354,"keywords":356,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":369,"locationsCount":370},"100521200","phase-3-precision-ventilation-vs-standard-care-for-acute-respiratory-distress-syndrome-100521200","NCT06066502","Precision Ventilation vs Standard Care for Acute Respiratory Distress Syndrome","PREcision VENTilation to Attenuate Ventilator-Induced Lung Injury: A Phase 3 Multicenter Randomized Clinical Trial","PREVENT VILI","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Ventilator-dependent ARDS, with all of the following (a-e):\n\n   1. Invasive ventilation with positive end-expiratory pressure (PEEP) ≥ 8 cm H2O or FiO2 ≥ 0.5\n   2. Hypoxemia as characterized by: • If arterial blood gas (ABG) available: the partial pressure of oxygen in the arterial blood (PaO2)\u002FFiO2 ≤ 300 mm Hg, or, • if ABG not available OR overt clinical deterioration in oxygenation since last ABG: SpO2\u002FFiO2 ≤ 316 with SpO2 ≤ 97% (both conditions) on two representative assessments between 1 to 6 hours apart. • If patient is positioned prone or receiving inhaled pulmonary vasodilator at time of screening:\n\n      Qualifying PaO2\u002FFiO2 or SpO2\u002FFiO2 (as defined above) that was recorded within the 6 hours immediately prior to initiating either of these therapies may be used for eligibility determination. • If PEEP has been increased by \\> 5 cm H2O within the last 12 hours immediately prior to screening:\n\n      Qualifying PaO2\u002FFiO2 or SpO2\u002FFiO2 (as defined above) prior to PEEP increase may be used for eligibility determination if recorded within this 12-hour window.\n   3. Bilateral lung opacities on chest imaging not fully explained by effusions, lobar collapse, or nodules\n   4. Respiratory failure not fully explained by heart failure or fluid overload\n   5. Onset within 1 week of clinical insult or new\u002Fworsening symptoms\n3. Early in ARDS course\n\n   * Full criteria for ARDS (#2 above) first met within previous 3 days\n   * Current invasive ventilation episode not more than 4 days duration\n   * Current severe hypoxemic episode (receipt of invasive ventilation, noninvasive ventilation, or high-flow nasal cannula) not more than 10 days duration\n\nExclusion Criteria:\n\n1. Esophageal manometry already in use clinically\n2. Severe brain injury: including suspected elevated intracranial pressure, cerebral edema, or Glasgow coma score (GCS) ≤ 8 directly caused by severe brain injury (e.g., ischemia or hemorrhage)\n3. Gross barotrauma or chest tube inserted to treat barotrauma (note: chest tube inserted strictly for drainage of pleural effusion is not an exclusion)\n4. Esophageal pathology that, in judgement of the site investigator, significantly increases risk of esophageal catheter placement, including high-risk esophageal varices, recent oropharyngeal or gastroesophageal surgery; or past esophagectomy\n5. Ongoing severe coagulopathy (platelet \\\u003C 5000\u002FμL or INR \\> 4)\n6. Extracorporeal membrane oxygenation (ECMO) or CO2 removal (ECCO2R)\n7. Neuromuscular disease that impairs spontaneous breathing (including but not limited to amyotrophic lateral sclerosis, Guillain-Barré syndrome, spinal cord injury at C5 or above)\n8. Any of the following severe chronic lung diseases: cystic fibrosis, acute bronchiectasis exacerbation, acute exacerbation of a chronic interstitial lung disease (ILD), chronic pulmonary hypertension (PH) on PH-targeted vasoactive medication, or lung transplant\n9. End-stage chronic cirrhosis with Child-Pugh Class C (Section 12.3)\n10. ICU admission for burn injury\n11. Current ICU stay \\> 2 weeks or acute care hospital stay \\> 4 weeks\n12. Moribund patient not expected to survive 24 hours as assessed by the study physician; if cardiopulmonary resuscitation (CPR) was provided, assessment for moribund status must occur at least 6 hours after CPR was completed\n13. Current limitation on life-sustaining care (other than do-not-resuscitate), or expectation by clinical team that a limitation on life-sustained care will be adopted within next 24 hours.\n14. Treating clinician refusal or unwilling to use protocol-specified ventilator settings\u002Fmodes\n15. Prisoner\n16. Previous enrollment in this trial",{"count":350,"type":22},1100,[352],"PHASE3","The goal of this interventional study is to compare standard mechanical ventilation to a lung-stress oriented ventilation strategy in patients with Acute Respiratory Distress Syndrome (ARDS). Participants will be ventilated according to one of two different strategies. The main question the study hopes to answer is whether the personalized ventilation strategy helps improve survival.",[355,201],"Acute Respiratory Distress Syndrome",[357,358,359,360,206,361],"critical care","critical illness","esophageal manometry","transpulmonary pressure","lung stress","2026-06-25",{"date":364,"type":43},"2026-06-29",{"date":366,"type":43},"2024-06-24",{"date":368,"type":22},"2030-12-31",{"name":49,"class":50},33,{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":378,"enrollmentInfo":379,"targetDuration":4,"studyType":23,"phases":381,"briefSummary":382,"conditions":383,"keywords":386,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":395,"leadSponsor":397,"locationsCount":4},"100629165","sleep-light-circadian-central-oxidative-stress-100629165","NCT07471126","Sleep, Light, Circadian, Central Oxidative Stress","Role of Ambien Lighting in Circadian Misalignment in a Chronic Variable Sleep Deficiency Paradigm: Impact on Sleep, Cognition, and Central Oxidative Stress","Inclusion Criteria:\n\n* Healthy participants 18-40 years old.\n\nExclusion Criteria:\n\n1. Volunteers must be drug-free (including caffeine, nicotine, and alcohol) for the entire duration of the study, with no history of drug or alcohol dependency.\n2. Subjects must be free from any significant impairments of the visual system, including color blindness.\n3. Subjects must be ambulatory, have no major visual or auditory handicaps, and be free from any major acute, chronic or debilitating medical conditions.\n4. history of psychiatric illnesses or psychiatric disorders\n5. History of consistent work during the overnight hours for the one year prior to study.\n6. History of transmeridian travel \\>2 times zones, will require a 1 week wash out per hour of time difference from the Eastern Standard\u002FDaylight Time zone.","40 Years",{"count":380,"type":22},40,[25],"Irregular sleep timing and sleep deficiency are pervasive in society despite evidence that sleep deficiency impairs cognition and is linked to neurodegenerative disease. Potential pathways underlying the adverse cognitive function and brain health associated with irregular insufficient sleep include misalignment of sleep from the internal \\~24-hour body clock and brain oxidative stress. This research will investigate these putative pathways and inform future interventions to mitigate the impact of sleep loss on cognition and brain health.",[384,385],"Non-visual Effects of Light","Chronic Variable Sleep Deficiency",[387,388,389,390],"Sleep","Circadian","Light exposure","Oxidative Stress","2026-06-09",{"date":393,"type":43},"2026-06-11",{"date":333,"type":22},{"date":396,"type":22},"2029-06-30",{"name":49,"class":50},{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":403,"acronym":404,"eligibilityCriteria":405,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":406,"targetDuration":4,"studyType":275,"phases":4,"briefSummary":408,"conditions":409,"keywords":411,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":391,"lastUpdatePostDateStruct":415,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":419,"locationsCount":51},"100477031","physiological-assessment-of-severe-coronary-stenosis-for-informing-planned-pci-100477031","NCT05491668","Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI","Physiological Assessment of Severe Coronary Stenosis for Informing Planned PCI (REFINE PCI)","REFINE PCI","Inclusion Criteria:\n\n* Age \\>\u002F= 18 years\n* Patient provides written informed consent\n* Clinical presentation with stable coronary artery disease or acute coronary syndromes (unstable angina, Non-ST Elevation Myocardial Infarction (NSTEMI), or ST Elevation Myocardial Infarction (STEMI))\n* Scheduled for clinically indicated cardiac catheterization\n* At least one lesion with angiographic severity visually estimated to be \\>\u002F= 70% diameter stenosis that is deemed suitable for PCI\n* The operator plans to perform PCI on an ad hoc or planned basis\n* The target lesion is not planned for assessment by invasive physiology\n\nExclusion Criteria:\n\n* Failure to provide signed informed consent\n* Culprit vessel of acute ST Elevation Myocardial Infarction (STEMI)\n* Culprit vessel of Non-ST Elevation Myocardial Infarction (NSTEMI)\n* Thrombolysis In Myocardial Infarction (TIMI) flow less than grade 3 at baseline or visible thrombus\n* Chronic total occlusion (CTO) in the target vessel\n* Target vessel is supplied by major collaterals or supplies major collaterals to a CTO\n* Target lesion involves the left main coronary artery\n* Prior history of coronary artery bypass grafting (CABG) to the target vessel, except if bypass graft is occluded\n* Previously known untreated severe valvular heart disease\n* Previously known left ventricular ejection fraction \\\u003C30%\n* Sustained ventricular arrhythmias\n* Patients who are currently pregnant (pregnancy testing will be performed as per standard cardiac catheterization laboratory protocol)",{"count":407,"type":22},107,"Traditionally, the severity of a blockage (stenosis) in a coronary artery has been determined by visual angiographic assessment of the diameter of the artery at the level of a blockage compared to a normal healthy area of the same artery. With the advent of invasive physiological testing to assess coronary blood flow, multiple clinical trials have demonstrated a clinical benefit to a physiology-guided percutaneous coronary intervention (PCI) approach. However, despite this and the potential for significant variation in the interpretation of coronary artery stenosis severity by visual angiography alone to guide PCI, invasive physiologic indices remain significantly under-utilized.\n\nThe purpose of this study is to investigate the physiologic significance of coronary lesions deemed angiographically severe by visual estimation that are planned for PCI. The investigators plan to perform blinded physiologic assessment pre and post PCI. The primary aim of the study is to determine whether a subset of lesions visually estimated as severe by angiography treated with stent placement\u002FPCI may in fact not be physiologically significant when assessed invasively, and thus PCI could safely be deferred in these patients. A secondary aim is to evaluate physiologic assessment post PCI to detect residual ischemia that could be utilized to optimize stent placement.",[410],"Coronary Artery Disease",[412,413,414],"Invasive physiology","Angiography","Percutaneous coronary intervention",{"date":393,"type":43},{"date":417,"type":43},"2022-10-11",{"date":188,"type":22},{"name":49,"class":50},{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":426,"eligibilityCriteria":427,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":428,"targetDuration":4,"studyType":23,"phases":430,"briefSummary":431,"conditions":432,"keywords":434,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":439,"lastUpdatePostDateStruct":440,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":51},"100637468","perioperative-high-flow-nasal-oxygen-in-patients-undergoing-robotic-surgery-100637468","NCT07591610","Perioperative High-flow Nasal Oxygen in Patients Undergoing Robotic Surgery","Perioperative High-flow Nasal Oxygen in Patients Undergoing Robotic Surgery: A Randomized Trial","Periop HFNO","Inclusion Criteria:\n\n* Age \\>= 18\n* Undergoing non-emergent, non-cardiac, intra-abdominal, intra-thoracic or pelvic robot-assisted surgery with an expected duration of at least 2 hours under general anesthesia with planned extubation at the end of the procedure\n\nExclusion Criteria:\n\n* Known pregnancy\n* Preoperative intubation or tracheostomy\n* Anatomical or clinical conditions precluding the use of high-flow nasal oxygen (severe midface trauma, recent nasal surgery, severe nasal septum deviation, severe nasal deformation)\n* Contraindications to electrical impedance tomography (EIT), including inability to place the EIT belt or presence of active implantable electronic devices (e.g., pacemaker or implantable cardioverter-defibrillator)\n* Planned postoperative admission to the intensive care unit",{"count":429,"type":22},190,[25],"The aim of the study is to assess whether perioperative use of high-flow nasal oxygen (HFNO) during the period from induction of anesthesia until discharge from the post-anesthesia care unit in patients undergoing robotic-assisted surgery reduces perioperative oxygen desaturation and postoperative pulmonary complications.",[433],"Robotic Surgery",[435,436,437,438],"Electric Impedance Tomography (EIT)","High-flow nasal oxygenation","Perioperative oxygenation","Robotic surgery","2026-06-01",{"date":441,"type":43},"2026-06-02",{"date":443,"type":22},"2026-08-01",{"date":445,"type":22},"2029-10-31",{"name":49,"class":50},{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":451,"acronym":452,"eligibilityCriteria":453,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":378,"enrollmentInfo":454,"targetDuration":4,"studyType":23,"phases":456,"briefSummary":457,"conditions":458,"keywords":460,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":475,"leadSponsor":477,"locationsCount":4},"100640252","effect-of-a-brief-daily-digital-meditation-on-well-being-in-us-young-adults-begin-ii-100640252","NCT07607782","Effect of a Brief Daily Digital Meditation on Well-Being in US Young Adults (BEGIN II)","BEGIN II","Inclusion Criteria:\n\n* Individuals between the ages of 18-40 years\n* Currently residing in the USA\n* Individuals who are English speaking\n* Willing and able to download an application on iOS\u002FAndroid\n\nExclusion Criteria:\n\n* Individuals who are non-English speaking\n* Unable to access an iOS\u002FAndroid smartphone\n* Individuals who regularly practice any form of meditation \\>4 times per week\n* Individuals scoring 9-12 on the PHQ-4, or ≥3 on either the PHQ-2 or GAD-2 subscale",{"count":455,"type":22},354,[25],"This study is testing whether a short, daily, app-based meditation can help young adults feel better in their everyday lives.\n\nWe will invite about 354 adults between 18 and 40 years old who live in the United States to join.\n\nEveryone who joins will be randomly placed into one of three groups for 4 weeks: Intervention group will do a 7-minute Miracle of Mind meditation each day using a phone app. Active comparator group will listen to a neutral 7-minute audio lesson each day. Control group will continue their usual daily routine without adding anything new.\n\nAll participants will answer short online surveys at the start and several times during the 4 weeks, sharing how they feel about their mood, stress, anxiety, overall well-being, and mindfulness.\n\nParticipants who already wear a smartwatch (like a Fitbit or Apple Watch) can choose to share their heart rate-related data so we can see whether the meditation might also affect physical signs of stress.\n\nInvestigators will compare how participants in the three groups change over time to see if the daily 7-minute meditation helps young adults feel better, less stressed, and more emotionally resilient.",[459],"Mental Health and General Well-being",[461,462,463,464,465,466,154,467,468,469,470],"Digital meditation","App-based guided meditation","Miracle of Mind meditation","Young adults mental health","Stress and anxiety reduction","Emotional well-being","Randomized controlled trial","Active and passive control groups","Well-being questionnaires","Physiological stress indicator","2026-05-21",{"date":473,"type":43},"2026-05-26",{"date":439,"type":22},{"date":476,"type":22},"2028-12-31",{"name":49,"class":50},{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":484,"eligibilityCriteria":485,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":486,"targetDuration":4,"studyType":23,"phases":488,"briefSummary":489,"conditions":490,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":493,"startDateStruct":495,"completionDateStruct":496,"leadSponsor":497,"locationsCount":4},"100634053","primed-to-thrive-investigating-the-combined-impact-of-mindfulness-education-and-meditation-practice-on-psychological-and-workplace-outcomes-100634053","NCT07534683","Primed to Thrive: Investigating the Combined Impact of Mindfulness Education and Meditation Practice on Psychological and Workplace Outcomes","Primed to Thrive: Investigating the Combined Impact of Mindfulness Education and Meditation Practice on Psychological and Workplace Outcomes (BEGIN III)","BEGIN III","Inclusion Criteria:\n\n* Individuals aged 18 years or older.\n* Current employee of the participating company who expresses interest in participating in the study.\n* Subjects will be required to be able to understand study instructions and materials and provide informed consent.\n* Willing and able to download and use a smartphone application compatible with iOS or Android platforms.\n\nExclusion Criteria:\n\n* Insufficient proficiency in English to comprehend study materials and instructions.\n* Presence of a diagnosed mental health condition that may interfere with the capacity to engage in or benefit from meditation practices, as determined by self-report or clinical history.",{"count":487,"type":22},134,[25],"Employees commonly experience stress and reduced well-being that can affect workplace functioning. This interventional study will evaluate whether combining mindfulness-related educational materials with a brief daily guided meditation practice delivered through a smartphone application improves psychological well-being and workplace outcomes compared with educational materials alone. Adult employees will be randomized to receive the meditation plus educational materials during the initial intervention period or after a waitlist period, with assessments completed at multiple time points over approximately 12 weeks. The primary outcome will evaluate change in work engagement using the Utrecht Work Engagement Scale (UWES-9).",[491],"Workplace Wellbeing","2026-05-12",{"date":494,"type":43},"2026-05-14",{"date":439,"type":22},{"date":318,"type":22},{"name":49,"class":50},{"id":499,"slug":500,"hasResults":12,"nctId":501,"briefTitle":502,"officialTitle":503,"acronym":504,"eligibilityCriteria":505,"healthyVolunteers":12,"sex":172,"minAge":378,"maxAge":506,"enrollmentInfo":507,"targetDuration":4,"studyType":23,"phases":509,"briefSummary":510,"conditions":511,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":492,"lastUpdatePostDateStruct":513,"startDateStruct":514,"completionDateStruct":516,"leadSponsor":518,"locationsCount":51},"100534428","study-on-allopregnanolone-and-depression-in-women-across-the-menopause-transition-100534428","NCT06238700","Study on Allopregnanolone and Depression in Women Across the Menopause Transition","Targeting Allopregnanolone to Probe Behavioral and Neurobiological Mechanisms That Underlie Depression in Women Across the Menopause Transition","SADIE-P","Inclusion Criteria:\n\n* Healthy women ages 40 to 60 years in the menopause transition\n* Depressive symptoms\n* Psychotropic medications are allowed if the dose is stable prior to screening and throughout the study\n* Able to read Arabic numerals and perform simple arithmetic\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Systemic hormone therapy\n* Contraindicated medications with pregnenolone\n* Systemic corticosteroid\n* Other psychiatric illnesses that are considered to be primary\n* Current suicidal ideation\n* Active substance use disorders\n* Unstable medical conditions\n* Obstructive sleep apnea or other primary sleep disorders\n* Abnormal hepatic and renal function\n* Known allergy to progesterone, exogenous allopregnanolone, or pregnenolone\n* History of head injury resulting in loss of consciousness \\> 20 min\n* Inability to comply with barrier contraceptive methods\n* Known intellectual disability\n* Investigator judgement that study participation constitutes substantial risk given medical or psychiatric condition\n* Current or recent participation in clinical trial expected to interfere with risk of or interpretation of study data\n* Inability to comply with study procedures","60 Years",{"count":508,"type":22},80,[25],"This study aims to identify how enhanced allopregnanolone activity (via pregnenolone) affects behavior and neurobiology that may underlie perimenopausal depression.",[512],"Depression",{"date":494,"type":43},{"date":515,"type":43},"2024-05-14",{"date":517,"type":22},"2027-08-31",{"name":49,"class":50},{"id":520,"slug":521,"hasResults":12,"nctId":522,"briefTitle":523,"officialTitle":523,"acronym":524,"eligibilityCriteria":525,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":526,"targetDuration":4,"studyType":275,"phases":4,"briefSummary":528,"conditions":529,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":535,"completionDateStruct":537,"leadSponsor":539,"locationsCount":51},"100408801","prevalence-and-impact-of-obstructive-sleep-apnea-in-multiple-sclerosis-100408801","NCT04603196","Prevalence and Impact of Obstructive Sleep Apnea in Multiple Sclerosis","SOMNUS","Inclusion Criteria:\n\n* Written consent\n* Over age 18\n* Confirmed diagnosis of multiple sclerosis\n\nExclusion Criteria:\n\n* cannot provide informed consent",{"count":527,"type":22},800,"This study will evaluate the influence of sleep apnea on clinical and radiological features of MS. Sleep apnea is associated with hypoxemia during sleep, which is likely detrimental to MS. Clinical data (MRI, lab results, medical history, labs, and sleep studies) of MS patients will be collected and analyzed. This will be done to study correlations between MRI, clinical data, lab studies and sleep studies. There is specific interest in the type of sleep apnea associated with MS, and whether MRI or clinical metrics of MS severity correlate with presence or absence of sleep apnea.",[530,531],"Multiple Sclerosis","Obstructive Sleep Apnea","2026-05-06",{"date":534,"type":43},"2026-05-11",{"date":536,"type":43},"2019-06-20",{"date":538,"type":22},"2030-06-20",{"name":49,"class":50},{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":545,"acronym":546,"eligibilityCriteria":547,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":548,"enrollmentInfo":549,"targetDuration":4,"studyType":275,"phases":4,"briefSummary":551,"conditions":552,"keywords":554,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":562,"lastUpdatePostDateStruct":563,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":569,"locationsCount":51},"100439733","pancreatic-cancer-screening-for-at-risk-individuals-100439733","NCT05006131","Pancreatic Cancer Screening for At-risk Individuals","Pancreatic Cancer Screening for At-risk Individuals (The Pancreas Scan Study)","PancreasScan","Inclusion Criteria:\n\n* Inclusion criteria 1-3 are indications for pancreatic cancer screening as defined by the CAPS3 guidelines or updated national pancreatic cancer screening guidelines. Patients who do not meet these guidelines but are undergoing pancreatic cancer screening at the discretion of their treating physician at participating study centers will also be included in the study. Based upon the indication for screening, patients will be categorized as either meeting CAPS3 screening criteria, or not meeting CAPS3 screening criteria.\n\n  1. Familial Pancreatic cancer kindred. This is defined as family history of pancreas cancer that meet the criteria listed below.\n\n     1. If at least two affected relatives who are First degree relatives (FDR) to each other, of whom at least one is an FDR to the individual considered for surveillance\n     2. If at least three affected relatives on the same side of the family, of whom at least one is an FDR to the individual considered for surveillance\n     3. If at least two affected relatives on the same side of the family, of whom at least one is an FDR to the individual considered for surveillance Screening is usually initialed at age 50 years or 10 years younger than the youngest family member with pancreatic cancer\n  2. Patients with genetic susceptibility to pancreas cancer\n\n     1. Patients with Peutz-Jeghers syndrome diagnosed with using clinical criteria or with a deleterious mutation in liver kinase B1\u002FSerine\u002Fthreonine kinase 11 (LKB1\u002FSTK11). Screening is usually initiated at age 40 years or later.\n     2. Patients with Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM syndrome), diagnosed using clinical criteria or CDKN2A p16 mutation.\n\nScreening is usually initiated at age 45 years or 10 years younger than the youngest family member with pancreatic cancer.\n\n1. Hereditary Breast and Ovarian Cancer syndrome: diagnosed using clinical criteria or deleterious Breast Cancer gene 1 (BRCA1), Breast Cancer gene 2 (BRCA2), Partner and Localizer of BRCA2 (PALB2). The usual indication for screening is:\n\n   * BRCA1 mutation and at least one affected first-degree relative with pancreatic cancer\n   * BRCA 2 mutation and at least one affected first-degree relative, or at least two relatives of any degree with pancreatic cancer\n   * PALB2 mutation and at least one affected first-degree relative with pancreatic cancer Screening is usually initiated at age 45 or 10 years younger than the youngest family member with pancreatic cancer; or per updated national screening guidelines\n2. Lynch syndrome or Ataxia Telangiectasia Mutated (ATM) mutations with at least one affected first-degree relative (FDR). Lynch syndrome could be diagnosed either by using clinical criteria or Mutator L homolog 1 (MLH1), Mutator S homolog 2 (MSH2), Mutator S homolog 6 (MSH6), Postmeiotic Segregation Increased, S. Cerevisiae, 2 (PMS2) or EPCAM mutation.\n\n   Screening to be initiated at age 45 or 10 years younger than the youngest family member with pancreatic cancer.\n3. Patients with hereditary pancreatitis diagnosed using clinical criteria or deleterious Serine Protease 1 (PRSS1) mutation. Screening is usually initiated at age 40 years or 10 years younger than the youngest family member with pancreatic cancer 3. New-onset diabetes, age \\> 50 years with weight loss. 4. Patients who do not meet these CAPS screening criteria but are determined by the site principal investigator to be high-risk for pancreatic cancer based upon family history or other risk factors, and are undergoing pancreatic cancer screening will also be included in the study. Indication for pancreatic cancer screening and age at which screening was initiated will be recorded.\n\nExclusion Criteria:\n\n* Patients presenting with symptoms suggestive of pancreatic cancer who are undergoing diagnostic EUS or MRCP e.g. acute recurrent pancreatitis, abnormal imaging","90 Years",{"count":550,"type":22},1395,"The investigators' goal is to conduct a prospective multicenter study to evaluate the yield and outcomes of screening of pancreas cancer in individuals who are at-risk for pancreatic cancer. We plan to use International Cancer of the Pancreas Screening (CAPS3) Consortium recommendations to standardize study population, screening methodology, and study outcomes.",[553],"Pancreatic Cancer, Adult",[555,556,557,558,559,560,561,152],"Pancreatic cancer screening","Early detection of pancreatic cancer","Genetic susceptibility to pancreatic cancer","BRCA 1","BRCA 2","familial pancreatic cancer","Endoscopic Ultrasound","2026-04-21",{"date":564,"type":43},"2026-04-23",{"date":566,"type":43},"2020-07-10",{"date":568,"type":22},"2032-12-31",{"name":49,"class":50},{"id":571,"slug":572,"hasResults":12,"nctId":573,"briefTitle":574,"officialTitle":575,"acronym":576,"eligibilityCriteria":577,"healthyVolunteers":12,"sex":18,"minAge":298,"maxAge":4,"enrollmentInfo":578,"targetDuration":4,"studyType":23,"phases":580,"briefSummary":581,"conditions":582,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":584,"lastUpdatePostDateStruct":585,"startDateStruct":586,"completionDateStruct":588,"leadSponsor":590,"locationsCount":51},"100357616","phase-3-statins-in-intracerbral-hemorrhage-100357616","NCT03936361","Statins In Intracerbral Hemorrhage","STATINS USE IN INTRACEREBRAL HEMORRHAGE PATIENTS","SATURN","Inclusion Criteria:\n\n1. Age ≥ 50 years.\n2. Spontaneous lobar ICH confirmed by CT or MRI scan\n3. Patient was taking a statin drug at the onset of the qualifying\u002Findex ICH\n4. Randomization can be carried out within 7 days of the onset of the qualifying ICH\n5. Patient or legally authorized representative, after consultation with the statin prescriber, agrees to be randomized to statin continuation (restart) vs. discontinuation\n\nExclusion Criteria:\n\n1. Suspected secondary cause for the qualifying ICH, such as an underlying vascular abnormality or tumor, trauma, venous infarction, or hemorrhagic transformation of an ischemic infarct.\n2. History of recent myocardial infarction (attributed to coronary artery disease) or unstable angina within the previous 3 months\n3. Diabetic patients with history of myocardial infarction or coronary revascularization\n4. History of familial hypercholesterolemia\n5. Patients receiving proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors\n6. Known diagnosis of severe dementia\n7. Inability to obtain informed consent\n8. Patients known or suspected of not being able to comply with the study protocol due to alcoholism, drug dependency, or other obvious reasons for noncompliance, such as unable to adhere to the protocol specified visits\u002Fassessments.\n9. Life expectancy of less than 24 months due to co-morbid terminal conditions.\n10. Pre-morbid mRS \\>3\n11. ICH score \\>3 upon presentation.\n12. Contraindications to continuation\u002Fresumption of statin therapy, such as significant elevations of serum creatinine kinase and\u002For liver transaminases, and rhabdomyolysis\n13. Woman of childbearing potential\n14. Concurrent participation in another research protocol for investigation of experimental therapy.\n15. Indication that withdrawal of care will be implemented for the qualifying ICH.",{"count":579,"type":22},1456,[352],"The SATURN trial aims to determine whether continuation vs. discontinuation of statin drugs after spontaneous lobar intracerebral hemorrhage (ICH) is the best strategy; and whether the decision to continue\u002Fdiscontinue statins should be influenced by an individual's Apolipoprotein-E (APOE) genotype.\n\nAn MRI ancillary study (SATURN MRI), in a subset of SATURN participants , will evaluate the effects of continuation vs. discontinuation of statin drugs on hemorrhagic and ischemic MRI markers of cerebral small vessel disease, and whether the presence\u002Fburden of hemorrhagic markers (i.e. cerebral microbleeds and\u002For cortical superficial siderosis) on baseline MRI influences the risk of ICH recurrence on\u002Foff statin therapy.",[583],"Intracerebral Hemorrhage","2026-04-19",{"date":562,"type":43},{"date":587,"type":43},"2020-06-10",{"date":589,"type":22},"2029-12",{"name":49,"class":50},{"id":592,"slug":593,"hasResults":12,"nctId":594,"briefTitle":595,"officialTitle":596,"acronym":597,"eligibilityCriteria":598,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":599,"targetDuration":4,"studyType":23,"phases":601,"briefSummary":602,"conditions":603,"keywords":605,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":609,"lastUpdatePostDateStruct":610,"startDateStruct":612,"completionDateStruct":613,"leadSponsor":615,"locationsCount":4},"100605277","phase-2-study-of-protection-and-repair-of-endothelial-glycocalyx-in-sepsis-spares-100605277","NCT07160426","Study of Protection And Repair of Endothelial-glycocalyx in Sepsis (SPARES)","Pilot Study of Protection And Repair of Endothelial-glycocalyx in Sepsis (SPARES)","SPARES","Inclusion Criteria:\n\n* Age ≥18 years\n* Confirmed or suspected infection (pathogen detected or antimicrobial administered)\n* SOFA score ≥2\n* ICU patient or ED patient with anticipated ICU admission\n\nExclusion Criteria:\n\n* Unable to randomize within 24h of meeting inclusion criteria\n* Current hospitalization \\>2 days\n* Decision to withhold life-sustaining treatment (exception for DNR only)\n* Moribund; not expected to survive 24h\n* Life expectancy \\\u003C28 days from non-sepsis condition\n* Any condition where participation isn't in the patient's best interest or limits assessments\n* Prisoner\n* Pregnancy\n* Concurrent interventional trial with overlapping treatments\u002Foutcomes\n* Inability to obtain patient\u002FLAR consent\n* History of Transfusion Related Acute Lung Injury (TRALI) or Transfusion Associated Circulatory Overload (TACO)\n* End Stage Renal Disease\n* Chronic tracheostomy with ventilator use",{"count":600,"type":22},45,[63],"Sepsis damages the blood vessel lining and its protective \"glycocalyx,\" contributing to organ failure and death. This pilot, randomized, blinded study will test whether giving fresh frozen plasma (FFP)-either as intermittent boluses or as a continuous infusion-protects or repairs the glycocalyx compared with look-alike placebo fluid (lactated Ringer's with multivitamins), and whether this leads to better clinical outcomes. We will measure blood and urine biomarkers of glycocalyx injury and track organ support needs, ICU\u002Fhospital-free days, and survival through 28-90 days.",[604],"Sepsis",[604,606,607,608],"Fresh Frozen Plasma","Endothelium","glycocalyx","2026-04-18",{"date":611,"type":43},"2026-04-22",{"date":333,"type":22},{"date":614,"type":22},"2028-12-01",{"name":49,"class":50},{"id":617,"slug":618,"hasResults":12,"nctId":619,"briefTitle":620,"officialTitle":621,"acronym":622,"eligibilityCriteria":623,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":624,"targetDuration":4,"studyType":275,"phases":4,"briefSummary":625,"conditions":626,"keywords":628,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":632,"startDateStruct":633,"completionDateStruct":635,"leadSponsor":637,"locationsCount":638},"100553872","eim-via-the-myolex-mscan-as-an-als-biomarker-100553872","NCT06491732","EIM Via the Myolex mScan as an ALS Biomarker","Electrical Impedance Myography Via the Myolex mScan as an ALS Biomarker","ElectricALS","Inclusion Criteria:\n\n* Sporadic or familial ALS diagnosed as clinically possible, probable, lab-supported probable, or definite ALS defined by revised El Escorial criteria\n* Capable of providing informed consent and complying with study procedures in the investigator's opinion\n* Time since ALS symptom onset ≤36 months\n* Vital Capacity of ≥40% of predicted capacity as measured by forced vital capacity or slow vital capacity\n* Must have a study partner for home visits\n* Access to the internet for data upload\n* Age 18 years or older\n\nExclusion Criteria:\n\n* Clinically significant unstable medical condition (other than ALS) that would affect the participant's ability to participate, according to the investigator's judgment\n* Patient with pure upper motor neuron disease (PLS)\n* Known history of unstable psychiatric disease, cognitive impairment, dementia, or active substance abuse\n* Significant pitting edema (2+ or more) that would interfere with EIM measures\n* Active cancer or history of cancer treated with chemotherapy and\u002For radiation\n* BMI \\>35",{"count":508,"type":22},"Amyotrophic lateral sclerosis (ALS) has been traditionally considered incurable and untreatable. But starting in the 1990s with the introduction of Riluzole, therapies are being discovered and ultimately approved for slowing disease progression. Many pharmaceutical companies continue to seek new therapeutic approaches. One critical aspect of all clinical trials is the need track to progression sensitively to identify the impact of therapy. Tools to track ALS progression must be convenient, objective, require minimal training, be easily standardized, cost-efficient, and have the potential to be applied effectively at home. There has been a push to identify accurate, objective biomarkers of ALS progression. In this study, the investigators propose to use Electrical impedance myography (EIM) to evaluate the progression of the disease. Work has shown that the EIM 50 kilohertz (kHz) phase value from one or more muscles, followed sequentially, can serve as an effective overall biomarker for assessing the rate of ALS progression for a single person.",[627],"Amyotrophic Lateral Sclerosis",[627,629,630],"Electrical Impedance Myography","Biomarker","2026-04-17",{"date":611,"type":43},{"date":634,"type":43},"2025-03-01",{"date":636,"type":22},"2027-05-30",{"name":49,"class":50},6,{"id":640,"slug":641,"hasResults":12,"nctId":642,"briefTitle":643,"officialTitle":644,"acronym":4,"eligibilityCriteria":645,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":646,"targetDuration":4,"studyType":23,"phases":648,"briefSummary":649,"conditions":650,"keywords":656,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":657,"startDateStruct":658,"completionDateStruct":660,"leadSponsor":662,"locationsCount":51},"100489655","phase-2-y-90-with-durvalumabgemcis-in-intrahepatic-cholangio-100489655","NCT05655949","Y-90 With Durvalumab\u002FGem\u002FCis in Intrahepatic Cholangio","A Single Arm Phase 2 Study of Y-90 SIRT in Combination With Durvalumab (MEDI 4736) and Gemcitabine\u002FCisplatin in Locally Advanced, Unresectable or Metastatic Intrahepatic Cholangiocarcinoma","Inclusion Criteria:\n\n* Ability to comprehend and willingness to sign a written ICF for the study\n* Male and female participants at least 18 years of age at the time of signing the ICF\n* Histologically or cytologically confirmed locally advanced unresectable or metastatic intrahepatic cholangiocarcinoma; at least one intrahepatic lesion must be present\n* Radiographically measurable or evaluable disease by CT or MRI per RECIST v1.1 criteria\n* ECOG performance status ≤1\n* Body weight \\>30 kg\n* Must have a life expectancy of at least 12 weeks\n* Participants must have adequate marrow function as defined below:\n\n  * Hemoglobin ≥9.0 g\u002FdL\n  * Absolute neutrophil count (ANC) ≥1.0 × 109 \u002FL\n  * Platelet count ≥75 × 109\u002FL\n* Participants must have adequate renal function as defined below:\n\n  * Serum creatinine ≤ 1.5 mg\u002FdL OR\n  * Measured creatinine clearance (CL) \\>40 mL\u002Fmin or Calculated creatinine CL\\>40 mL\u002Fmin by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance\n* Participants must have adequate hepatic function as defined below:\n\n  * Bilirubin ≤1.5 x ULN\n  * ALT ≤ 2.5 x ULN unless liver metastases are present, in which case it must be ≤5x ULN\n  * AST ≤ 2.5 x ULN unless liver metastases are present, in which case it must be ≤5x ULN\n  * This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician\n  * No known history of active HBV or HCV infection.\n\n    * Note: Participants with Hepatitis C who have been clinically cured, defined as persistent absence of Hepatitis C RNA detected by polymerase chain reaction (PCR) test in serum 12 weeks after completing antiviral treatment, are eligible for this study\n    * Note: Participants with a history of Hepatitis B infection that are currently on viral suppressive therapy are eligible for enrollment\n* Adequate coagulation studies as demonstrated by prothrombin (PT) and partial thromboplastin (PTT) time within normal limits (\\\u003C\u002F= 1.5 x ULN) in the absence of anticoagulation medication. Participants receiving anticoagulation may be approved by sponsor\n* Participants with known human immunodeficiency virus (HIV) on effective highly-active antiretroviral therapy (HAART) with undetectable viral load within 6 months are eligible for this trial, so long as the following criteria are met:\n\n  * HAART does not interact with or have overlapping toxicities with study medication, per discretion of the treating provider\n  * CD4 count is ≥350 cells\u002FuL, viral load is undetectable, and not taking prohibited cytochrome (CYP)-interacting medications\n  * Probable long-term survival with HIV if cancer were not present\n  * Stable on a HAART regimen for ≥4 weeks and willing to adhere to their HAART regimen with minimal overlapping toxicity and drug-drug interactions with the experimental agents in this study\n  * HIV is not multi-drug resistant\n  * Taking medication and\u002For receiving antiretroviral therapy that does not interact or have overlapping toxicities with the study medication\n\nExclusion Criteria:\n\n* Surgically resectable disease at enrollment\n* Histologically or cytologically confirmed diagnosis of primary hepatocellular carcinoma or mixed adenocarcinoma\u002Fhepatocellular carcinoma\n* Received prior systemic chemotherapy and\u002For radiotherapy for intrahepatic cholangiocarcinoma. Prior surgical resection and adjuvant chemotherapy or chemoradiotherapy is allowed if more than 6 months have elapsed since last dose of treatment, and if the tumor is amenable to Y-90 SIRT\n* Prior treatment with anti-PD-1, anti-PD-L, including durvalumab antibody, or any other drug treatment specifically targeting T-cell co-stimulation or checkpoint pathways\n* Any of the following within 6 months of screening:\n\n  * New York Heart Association (NYHA) Class III or IV heart failure\n  * Myocardial infarction, unstable angina pectoris, or symptomatic coronary artery disease\n  * Unstable arrhythmia\n  * Stroke to transient ischemic attack\n* Previous malignancies, except for adequately treated non-melanoma skin cancer, in-situ cancer, or any other cancer from which the subject has been disease-free for at least 3 years\n* Severe chronic obstructive or other pulmonary disease with chronic baseline hypoxemia due to potential for gemcitabine-induced bronchospasm and\u002For durvalumab-induced pneumonitis\n* Major surgery (other than diagnostic) within 4 weeks of study treatment day 1\n* Active, uncontrolled or untreated bacterial, viral, or fungal infection that requires systemic therapy\n* Active, untreated HIV, HBV, or HCV\n* Subjects who have participated in another investigational drug or device study within 4 weeks prior to study registration.\n\nPregnant women are excluded from this study because cisplatin is a class D agent with the potential for teratogenic or abortifacient effects. Because cisplatin is present in breast milk and there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with cisplatin, breastfeeding should be discontinued prior to entry into the study. Subjects and their sexual partners entered into the study must agree to contraception. The following restrictions apply while the patient is receiving study treatment and for the specified times before and after:\n\n* Female patients of child-bearing potential Female patients of childbearing potential who are not abstinent and intend to be sexually active with a non sterilized male partner must use at least 1 highly effective method of contraception (Table 2) from the time of screening throughout the total duration of the drug treatment and the drug washout period (90 days after the last dose of durvalumab monotherapy). Non-sterilised male partners of a female patient of childbearing potential must use male condom plus spermicide throughout this period. Cessation of birth control after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Female patients should also refrain from breastfeeding throughout this period.\n* Male patients with a female partner of childbearing potential Non-sterilized male patients who are not abstinent and intend to be sexually active with a female partner of childbearing potential must use a male condom plus spermicide from the time of screening throughout the total duration of the drug treatment and the drug washout period (90 days after the last dose of durvalumab monotherapy). However, periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Male patients should refrain from sperm donation throughout this period.\n\nFemale partners (of childbearing potential) of male patients must also use a highly effective method of contraception throughout this period (Table 2).\n\nFemales of childbearing potential are defined as those who are not surgically sterile (ie, bilateral salpingectomy, bilateral oophorectomy, or complete hysterectomy) or post-menopausal.\n\nWomen will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:\n\n* Women \\\u003C50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution.\n* Women ≥50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses \\>1 year ago, had chemotherapy-induced menopause with last menses \\>1 year ago.\n\nHighly effective methods of contraception, defined as one that results in a low failure rate (ie, less than 1% per year) when used consistently and correctly are described in Table 2. Note that some contraception methods are not considered highly effective (e.g. male or female condom with or without spermicide; female cap, diaphragm, or sponge with or without spermicide; non-copper containing intrauterine device; progestogen-only oral hormonal contraceptive pills where inhibition of ovulation is not the primary mode of action \\[excluding Cerazette\u002Fdesogestrel which is considered highly effective\\]; and triphasic combined oral contraceptive pills).\n\n* Copper T intrauterine device\n* Levonorgestrel-releasing intrauterine system (e.g., Mirena®)a\n* Implants: Etonogestrel-releasing implants: e.g. Implanon® or Norplant®\n* Intravaginal: Ethinylestradiol\u002Fetonogestrel-releasing intravaginal devices: e.g. NuvaRing®\n* Injection: Medroxyprogesterone injection: e.g. Depo-Provera®\n* Combined Pill: Normal and low dose combined oral contraceptive pill\n* Patch: Norelgestromin\u002Fethinylestradiol-releasing transdermal system: e.g. Ortho Evra® Minipillc: Progesterone based oral contraceptive pill using desogestrel: Cerazette® is currently the only highly effective progesterone-based\n\n  * Any concomitant disease or condition that could interfere with the conduct of the study, or that would in the option of the investigator pose an unacceptable risk to the subject in the study\n  * Contraindications to Y-90 SIRT per assessment by treating Interventional Radiologist (eg significant vascular drainage of the tumor to the lung that increases the potential for pulmonary toxicity)\n  * Unwillingness or inability to comply with the study protocol\n  * History of allogenic organ transplantation.\n  * Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \\[e.g., colitis or Crohn's disease\\], diverticulitis \\[with the exception of diverticulosis\\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \\[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc\\]). The following are exceptions to this criterion:\n\n    * Patients with vitiligo or alopecia\n    * Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement\n    * Any chronic skin condition that does not require systemic therapy\n    * Patients without active disease in the last 5 years may be included but only after consultation with the study physician\n    * Patients with celiac disease controlled by diet alone\n  * Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent\n  * History of active primary immunodeficiency\n  * Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice\n  * Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. The following are exceptions to this criterion:\n\n    * Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection)\n    * Systemic corticosteroids at physiologic doses not to exceed \\\u003C\\\u003C10 mg\u002Fday\\>\\> of prednisone or its equivalent\n    * Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)\n  * Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IP.\n  * Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy.\n  * Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.",{"count":647,"type":22},30,[63],"This trial is designed to study a combination of interventions (chemotherapy, immunotherapy, and radiation) as a potential new treatment for bile duct cancer that cannot be removed with surgery.\n\nThe specific names of the interventions that will be used are:\n\n* Y-90 (a type of radiation microsphere bead)\n* Durvalumab (a type of immunotherapy)\n* Gemcitabine (a type of chemotherapy)\n* Cisplatin (a type of chemotherapy)",[651,652,653,654,655],"Bile Duct Cancer","Cholangiocarcinoma","Cholangiocarcinoma Non-resectable","Cholangiocarcinoma Metastatic","Metastatic Intrahepatic Cholangiocarcinoma",[651,652,653,654,655],{"date":611,"type":43},{"date":659,"type":43},"2024-02-13",{"date":661,"type":22},"2027-12-01",{"name":49,"class":50},""]